- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939854
Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage
A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage
This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Yong Cao
- Numéro de téléphone: +86 13601362306
- E-mail: caoyong@bjth.org
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100070
- Recrutement
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Yong Cao
- Numéro de téléphone: +86 13601362306
- E-mail: caoyong@bjth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 years and <80 years.
- Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
- Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
- A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
- Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
- Randomization initiated between 6 and 12 hours after the diagnostic CT.
- Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.
Exclusion Criteria:
- Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
- Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
- The predominant portion of the hematoma involves the midbrain or medulla.
- Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
- Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
- Previous history of brainstem hemorrhage.
- Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
- An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
- CT evidence indicating a high risk of rebleeding, including a spot sign.
- Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
- Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
- Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
- Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
- Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
- Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
- Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
- Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
- Known hypersensitivity to tenecteplase.
- Previous participation in this study with completed randomization.
- Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
- Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
- Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
- Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
- Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
- Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
- The participant requests conservative treatment or conventional open microsurgical treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Stereotactic Aspiration Combined With Tenecteplase
Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment. |
Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization. Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.
Autres noms:
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
|
Comparateur actif: Standard Medical Treatment
|
Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of Participants With GCS Score >8
Délai: 90 days after randomization
|
Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. |
90 days after randomization
|
|
All-Cause Mortality
Délai: Within 30 days after randomization.
|
Proportion of participants who die from any cause within 30 days after randomization. |
Within 30 days after randomization.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
7-Day All-Cause Mortality
Délai: Within 7 days
|
Within 7 days
|
|
Symptomatic Rebleeding
Délai: Within 72 hours after tenecteplase administration
|
Within 72 hours after tenecteplase administration
|
|
Intracranial Bacterial Infection
Délai: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
Délai: Within 30 days
|
Within 30 days
|
|
Adverse Events (AEs)
Délai: Within 30 days
|
Within 30 days
|
|
Serious Adverse Events (SAEs)
Délai: Within 365 days
|
Within 365 days
|
|
Adverse Events (AEs)
Délai: Within 365 days
|
Within 365 days
|
|
Proportion With GCS Increase ≥3 Points
Délai: 30 days
|
30 days
|
|
Proportion With Recovery of Consciousness
Délai: 30 days
|
30 days
|
|
Proportion With mRS 0-3
Délai: 90 days
|
90 days
|
|
Proportion With mRS 0-3
Délai: 365 days
|
365 days
|
|
Change in GCS Score Over Time
Délai: From baseline through 90 days after randomization
|
From baseline through 90 days after randomization
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LX-2026-0001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .